In order to investigate the anti-tumor activity of a soluble B7-1/immunoglobulin G fusion protein and explore an effective method to eliminate immune escape of tumor cells, a recombinant vector encoding this fusion protein was constructed and constitutively expressed in Chinese hamster ovary cells. After purification with protein G affinity chromatography, the soluble fusion protein was tested for bioactivity. Results showed that the fusion protein could significantly increase the density of B7-1 molecules on WEHI-3 cells, a mouse leukemia cell line. Through allogeneic mixed lymphocyte tumor cultures, it was demonstrated that, with the presence of the first signal, it could also significantly enhance T cell activation and killing activity against WEHI-3 cells and interleukin-2 secretion by activated mouse T lymphocytes. The conclusion can be drawn that the soluble B7-IgG fusion protein has a potent capacity to generate or enhance anti-tumor immune response in vitro, and its clinical value deserves further investigation.
INTRODUCTION
Generally, the normal anti-tumor immune response is initiated by occupancy of the T-cell receptor complex by tumor antigens processed and presented by APCs in association with the major histocompatibility complex, and by interaction of the adhesive molecules on APCs with their counterreceptors on T cells; these are respectively known as the first signal and the second signal (co-stimulatory signal) for T-cell activation. The first signal alone, lacking a co-stimulatory signal, leads to anergy or tolerance of tumor-specific T cells, and this has been established as the main mechanism by which some tumor cells escape host immunosurveillance (Whiteway et al., 2003) , in that they can function as APCs. These tumor cells do not express B7 molecules on the surface of their membrane, or the expression is downregulated (Whiteway et al., 2003) by this means, they eliminate the critical co-stimulatory signal provided by the interaction of B7 molecules with their ligands on T cells (T-cell surface protein CD28 and/or CTLA-4). Any measures that effectively promote the expression of B7 molecules on the surface of tumor cells can at least partly restore their immunogenicity by signaling through the co-stimulatory pathway. It has been proved that transfection or transduction of the B7 gene into tumor cells can upregulate B7 molecule expression and thereby enhance anti-tumor immunity to some extent (Mutis et al., 1998) . However, because of the low efficiency and time limitations of gene expression, the available B7 molecules are insufficient for full activation of tumor-specific T cells (Stein et al., 1991) . The relative insufficiency of B7 gene transfection in tumor therapy can also be explained by its binding with CTLA-4 on activated T cells, which triggers a negative signal and facilitates immune tolerance to tumor cells (Bluestone, 1997) . Here, we constructed a recombinant expressing vector by fusing a cDNA encoding the mouse IgG Fc fragment to a cDNA encoding the extracellular portion of mouse B7-1 antigen, which could generate a soluble fusion protein named B7-IgG. We presumed that this fu-sion protein, though lacking the transmembrane and intracellular portions of the B7-1 molecule, would be sufficient for interaction with CD28 or CTLA-4 and would co-stimulate T lymphocytes. The Fc portion should permit its binding to the membrane of mouse leukemic cells via their highly expressed specific Fcγ receptors, which may upregulate expression of B7 molecules on leukemic cells and largely eliminate their immune escape. Also, we thought that the introduction of the soluble IgG Fc portion would give the molecule some new properties favoring the antitumor immune response.
MATERIALS AND METHODS

Construction of recombinant vector.
The cDNA encoding the signal and extracellular domains of the mouse B7 molecule (termed cDNA-B7) was amplified from plasmid pcDNA/B7 containing the full-length cDNA of the mouse B7 molecule (a generous gift from Professor Qu Shen, Biochemistry Department, Tongji Medical College, Huazhong University of Science and Technology, China) with the following primers : forward 1 : 5'-GCC GCT TAA GCT TCA TCT GAA GCT ATG GCT-3' and reverse 1 : 5'-GCA CGA ATT CTG TGT TCT TGC TAT CAG G-3'. HindIII and EcoRI restriction enzyme sites were introduced into the above primers. The cDNA encoding the Fc portion (the hinge-CH2-CH3 domains of mouse IgG1, termed cDNA-IgG) was obtained by reverse-transcription polymerase chain reaction (RT-PCR) with total RNA isolated from spleen cells of 8-week-old Balb/c mice (purchased from the Experimental Animal Center of Tongji Medical College). The primers were : forward 2 : 5'-GCA CGA ATT CAG CAC CAA GGT GGA CAA G-3' and reverse 2 : 5'-GCC ACT CGA GCC AAG GAC ACT GAG ATT A-3', into which EcoRI and XhoI restriction enzyme sites were introduced. Forward 1 included the initiation codon ATG and Reverse 2 included the termination codon TGA. To construct the pcDNA/B7-IgG recombinant vector, the plasmid pcDNA3.0 (kindly provided by Professor Guanxin Shen, Immunology Department, Tongji Medical College) and cDNA-IgG underwent double digestion with EcoRI and XhoI (Fermentas, Lithuania). After purification by phenol and chloroform, the cleavage products were ligated with T4 DNA ligase (Promega, USA) and then transformed into Escherichia coli strain DH5α (generously provided by Professor Guanxin Shen). The transformants were singled out and plasmid DNA was isolated and identified on agarose gel by double digestion with EcoRI + XhoI and DNA sequencing. The correct recombinant was named pcDNA/IgG. Next, pcDNA/IgG and cDNA-B7 were subjected to double digestion with HindIII + EcoRI. After purification, ligation and transformation as described above, the products were verified on agarose gel by double digestion with HindIII + EcoRI, EcoRI + XhoI and HindIII + XhoI and DNA sequencing. The correct recombinant was named pcDNA/B7-IgG.
Cell transfection and expression. CHO cells were purchased from the China Center for Type Culture Collection (Wuhan, China) and maintained in DMEM/F12 medium (Gibco BRL, USA) containing 10% fetal bovine serum (FBS), 100 u/ml penicillin and 100 mg/l streptomycin at 37 o C in a 5% CO 2 incubator. The pcDNA/B7-IgG plasmid was isolated and purified with a QIAGEN Maxi Plasmid Preparation Kit (Qiagen), and transfected into exponentially growing CHO cells with a liposome-mediated cell transfection kit (SuperFect Transfection Reagent, Qiagen), according to the manufacturer's instructions. The clones that survived G418 (Sigma, USA) selection (1-week incubation in DMEM/F12 medium containing 0.8 g/l G418 at 37 o C) were carefully isolated and transferred into DMEM/F12 medium containing 0.3 g/l G418 for another 3-week incubation. A cell population with high constitutive expression of B7-IgG fusion protein was obtained and expanded, and some were then cryopreserved in liquid nitrogen. The control was the pcDNA3.0 plasmid. Supernatant of these surviving clones was collected and subjected to Western blotting under reducing conditions as previously described (Cai et al., 2002) . The primary antibody was a goat polyclonal antibody raised against a peptide mapping at the amino terminus of CD80 of mouse origin (Santa Cruz, USA). The secondary antibody was HRP-conjugated rabbit anti-goat IgG (Zhongshan Biotech Co. Ltd., China). Luminol Reagent (Santa Cruz, USA) was used for enhanced chemiluminescence detection of Western blots. To perform dot ELISA, concentrated supernatants were dotted on nitrocellulose membrane (Sigma, USA) with serial dilution at 1 : 1, 1 : 2, 1 : 4, 1 : 8 and 1 : 16. A mouse IgG Fc fragment-specific HRPconjugated goat antibody (Biodesign, USA) was used for dot ELISA detection of B7-IgG as mentioned previously (Dalimi et al., 2004) . The supernatant of the pcDNA3.0-transfected cell culture was regarded as negative control.
Purification of fusion protein. The CHO cells constitutively expressing the fusion protein were maintained in DMEM/F12 medium containing 0.3 g/l G418. When they were at 30−40% confluence, the medium was removed and the cells were washed three times with serum-free DMEM/F12 medium; some OPTI-MEM reduced serum medium (Gibco BRL, USA) supplemented with 0.1 g/l calcium chloride was then added and incubation continued. When these cells were at more than 90% confluence, the supernatant was harvested and centrifuged at 1000 × In vitro B7 co-stimulation g for 10 min to eliminate cell debris. The fusion protein was isolated and purified from the supernatant by immune affinity chromatography with HiTrap Protein G affinity columns (Amersham Bioscience) according to the manufacturer's instructions. Briefly, 0.02 mol/l sodium phosphate (pH 7.0) was prepared as the binding buffer and 0.1 mol/l glycine/HCL (pH 2.7) as the elution buffer. The harvested supernatant (200 ml) was concentrated by lyophilization and desalted by dialysis. The column was washed with 10 column volume of binding buffer, and a peristaltic pump was used to pass the sample through the column. After washing the column with 10 column volumes of binding buffer, the binding fusion protein was eluted with five column volumes of elution buffer. The eluted proteins were pooled and assayed by SDS/PAGE and Western blot as previously described, and then dialyzed overnight and sterilized by passing through 0.2 µm syringe filter units. The concentration was determined by the UV absorbance at 280 nm.
Effects of fusion protein on B7 density on leukemic cells. WEHI-3 cells were purchased from the Chinese Academy of Medical Science and were maintained in suspension culture in DMEM medium supplemented with 10% FBS, 100 u/ml penicillin and 100 mg/l streptomycin at 37 o C in a 5% CO 2 incubator. Exponentially growing WEHI-3 cells were collected and washed three times with cold phosphate-buffered saline (PBS), and the cell density was adjusted to 1.0 × 10 6 /ml. After staining with a FITCconjugated anti-mouse CD80 monoclonal antibody (Southern Biotech, USA) and an R-phycoerythrinconjugated anti-mouse CD32 monoclonal antibody (Southern Biotech, USA), the cells were washed once with PBS and subjected to flow cytometry analysis. Irrelevant monoclonal antibodies of isotypes IgG1 and IgG2 (PharMingen, USA) served as negative controls. Next, WEHI-3 cells were preincubated at 4 o C for 1 h with the fusion protein (6 µg/10 6 cells (Zheng et al., 2001) ) and washed extensively with PBS. After staining with FITC-anti-mouse CD80, the cells were subjected to flow cytometric analysis as described above.
T-cell proliferation assay and interleukin-2 secretion. Splenic cell suspension was obtained from a 6-week-old Balb/c mouse and mononuclear cells were isolated by Ficoll-Hypaque gradient centrifugation. Contaminating erythrocytes were removed by hypotonic lysis. Monocytes were removed by plastic adherence for 3 h in RMPI 1640 (Gibco BRL, USA) plus 10% FBS at 37 o C in 5% CO 2 incubator. T cells were enriched by passing through a nylon wool column and their purity was determined by flow cytometry with a FITC-conjugated anti-mouse CD3 monoclonal antibody (mAb, BioLegend). Purified anti-mouse CD3 mAb (17A2, BioLegend) was added at 25 µg/ml into wells in flat-bottom 96-well plates and incubated at 4 o C overnight in coating buffer consisting of 50 mmol/l Tris/HCl (pH 9.5) followed by extensive washing with RMPI 1640. T-cell proliferation reaction was assessed by incubating 1 × 10 5 purified T cells in flat-bottom 96-well plates in triplicate with or without B7-IgG protein (6 µg/10 6 cells). T cell culture alone was regarded as a natural control. After 3-day incubation, these incubated T cells were pulsed with 1 μCi [ 3 H]thymidine per well for another 16 hours. The [ 3 H]TdR incorporation was measured by liquid scintillation counting to estimate the proliferation of lymphocytes. Likewise, the microculture system was repeated as mentioned above and the culture supernatant was aspirated at incubation day 2 and day 5 and assayed for interleukin-2 (IL-2) concentrations with mouse IL-2 ELISA kit (Jingmei Biotech, China) according to its handbook.
Allogeneic mixed lymphocyte tumor cultures. A splenic cell suspension was obtained from a 6-week-old Balb/c mouse and the MNCs were isolated by Ficoll-Hypaque gradient centrifugation. MNCs (1.0 × 10 6 ) were activated with 5 mg/l PHA for 3 days in RMPI 1640 supplemented with 10% FBS at 37 o C in a 5% CO 2 incubator, followed by washing once, and cultured in RMPI 1640 medium for 1 day; these were regarded as responding cells (R). After inactivation by incubating 5 × 10 6 cells per 1 ml DMEM medium in 1 g/l mitomycin C (Sigma, USA) at 37 o C in 5% CO 2 for 1 h, WEHI-3 cells were preincubated in RMPI 1640 medium containing B7-IgG protein (6 µg/10 6 cells) or the medium alone (regarded as a control) at 4 o C for 1 h and then carefully washed with PBS; these served as stimulating cells (S). For allogeneic mixed lymphocyte tumor culture, 5 × 10 5 /100 µl PHA-activated mouse MNCs (R) were carefully and completely mixed with 1.0 × 10 6 /100 μl stimulating cells (S), resulting in an R : S ratio of 1 : 2, and then transferred to the microwells of flatbottom 96-well plates coated with anti-CD3 mAb as described above. They were incubated at 37 o C in a 5% CO 2 incubator for 7 days, then the cytotoxic activity of the microcultures was determined by standard lactate dehydrogenase (LDH)-release assay. Briefly, exponentially growing WEHI-3 cells (not inactivated by mitomycin C) were used as target cells (T). The effector cells (E) and the target cells were carefully and completely mixed with an E : T ratio of 25 : 1, added to 96-well flat-bottom plates (Corning, USA) with a final volume of 0.2 mL per well, and then incubated for 4 h in triplicates at 37 o C in a 5% CO 2 incubator. The maximum release (M) of LDH activity was determined by lysing the target cells with 1% NP40, and the spontaneous release (S) of LDH activity from target cells was detected by culturing WEHI-3 cells in culture medium alone. After incubation, the enzymatic reactions were carried out in the dark over 15 min as previously described (Konjevic et al., 1999) . Release of LDH from tumor cells was expressed as absorbance at 490 nm. The percentage of effector cell activity was calculated by the formula : cytotoxic activity = (E−S)/(M−S) × 100%. All reagents were purchased from Sigma (St Louis, MO, USA).
Statistical analysis. All data were expressed as mean ± S.D. and differences between groups were considered to be significant at P < 0.05. Oneway analysis of variance was performed to estimate significant differences among groups by means of SPSS10.0, and vertical bar charts were created with SigmaPlot 8.0.
RESULTS
The recombinant vector was successfully constructed
By 1.5% agarose gel electrophoresis analysis, the sizes of cDNA-B7 (729 nucleotides, 243 amino acids) and cDNA-IgG (723 nucleotides, 241 amino acids) were confirmed to be about 750 bp, containing some attached bases. After digestion with EcoRI + XhoI, the recombinant pcDNA/IgG released two DNA fragments; one was about 750 bp, which should be cDNA-IgG and the other was about 5.4 kb, which was the remaining bases of pcDNA3.0. Various double digestions, including HindIII + EcoRI, EcoRI + XhoI and HindIII + XhoI, were performed to confirm that the recombinant pcDNA/B7-IgG contained the two target cDNA fragments in tandem. DNA sequencing showed that the cDNA sequences of the two fragments were identical to the reported sequences, and they had been cloned in tandem into pcDNA3.0 with a correct open reading frame. The conclusion could be drawn that the recombinant vector of pcDNA/B7-IgG had been constructed successfully.
Constitutive expression, identification and purification of B7-IgG fusion protein. As shown in Fig. 1A and 1B, an antigen was present in the supernatant of the G418-selected CHO cell population that could be recognized not only by a specific antibody targeted at the extracellular portion of B7-1, but also by an IgG Fc fragment-specific antibody. Its molecular mass was 70−100 kDa. However, none of the controls contained this antigen. Theoretically, the calculated molecular mass of this fusion protein monomer is about 55 kDa, as it contains about 484 amino acids. However, if glycosylation is taken into account, it should be a little greater. Hence, we considered this to be the B7-IgG fusion protein that we had constructed. Figure 1C shows that the purified fusion protein migrated at approx. 66−97 kDa in SDS/PAGE under reducing conditions. Western blotting analysis showed a specific band at the expected site (not shown), which coincided with what was proven previously. According to these data combined with the absorbance of the protein solution at 280 nm, we measured the concentration of the fusion protein to be about 0.1 mg/ml and the purity more than 90%. In all, 20 mg of the fusion protein was obtained from 200 ml of cell culture supernatant.
Density of B7-1 molecules on leukemic cells was increased by fusion protein
As shown in Fig. 2 , the very low expression of B7-1 molecules and the very high expression of CD32 molecules on WEHI-3 cells indicated that the WEHI-3 cell line was suitable for our experimental model. After preincubation with the fusion protein, WEHI-3 cells showed a significant (P < 0.01) increase in the density of B7-1 molecules on their membrane. Figure 3A and 3B show that, in the presence of the first signal imitated by anti-CD3 mAb, B7-IgG protein could dramatically co-stimulate purified mouse T cells to proliferate by providing them with the second signal; the first signal alone could not. These co-stimulated T cells secreted much more a a IL-2 than those primed by anti-CD3 mAb alone to further enhance this effect, although the increase in IL-2 secretion could be completely accounted for by the increase in T-cell proliferation. It is worth noting that, after a 5-day incubation, T cells co-stimulated by the fusion protein together with anti-CD3 could still maintain a high IL-2 level (P > 0.05), but other T cells could not (P < 0.05). We presumed that this was because the fusion protein could promote continuous secretion of IL-2 for at least 5 days and maintain activation and proliferation of T lymphocytes.
Co-stimulation of T-cell proliferation and enhancement of IL-2 secretion
Enhanced cytotoxicity against allogeneic tumor cells
The lytic activity of lymphocytes against WEHI-3 cells is positively associated with LDH release. The results (shown in Table 1) suggested that B7-IgG-treated tumor cells, which resulted in pronounced upregulation of B7 expression on the cells, had a significantly increased susceptibility to killing by primed lymphocytes. Treatment without the fusion protein did not cause pronounced cytotoxicity against tumor cells. This observation showed the ability of the B7-IgG fusion protein to co-stimulate lymphocytes and enhance their cytotoxicity against target cells.
DISCUSSION
B7 is a member of the Ig superfamily, which is mainly expressed on APCs. B7-1 and B7-2 (CD86) are two important molecules of the family. By binding with their two main ligands, CD28 and/or CTLA-4, they provide the most important co-stimulatory signal for the T cell proliferative response and induction of effector function. However, ligation of B7 and CTLA-4 generates a negative signal for immune response, and only the interaction of B7 and CD28 can induce proliferation and lymphokine secretion. If the antigen is presented to APCs without the costimulatory signal, antigen-specific T cells become non-responsive. Many tumor cells, especially AML cells, can function as APCs, but impaired expression of B7 on their membrane makes it very easy CD32 expression rate (A) was about (89.48 ± 3.05)% (n = 5). Before treatment with fusion protein, CD80 density (B) on the membrane of WEHI-3 cells was about (5.06 ± 0.41)% (n = 5), but after preincubation with fusion protein, CD80 density (C) was significantly upregulated to (27.36 ± 2.15)% (n = 4, P < 0.01). A. The measured [ 3 H]TdR incorporation is the average of five independent experiments, and with co-stimulation by B7-IgG+anti-CD3, it was significantly increased (compared with that of the control, P < 0.05); however, that of anti-CD3 alone was not (P < 0.05). B. IL-2 concentration is shown as the average of five independent experiments. Compared with the control, the IL-2 concentration increase after co-stimulation by B7-IgG and anti-CD3 was statistically significant (P < 0.05), but that with anti-CD3 alone was not (P < 0.05). All data are represented as mean ±S .D. for them to escape host immune system surveillance and attack (Whiteway et al., 2003) . Although CD86 is a more important source of the co-stimulatory signal, maybe because its intracellular portion is longer than that of CD80, many data show there is much more seriously impaired expression of CD80 than CD86 on tumor cells (Matsumoto & Anasetti, 1999) and transfection with the CD80 gene, which results in expression of CD80 molecules, could more effectively protect established animal models from tumor cell rechallenge and relapse from minimal residual disease (Matulonis et al., 1996) . With a view to increasing the expression of CD80 molecules on tumor cells, we constructed a B7-IgG fusion protein containing the signal peptide and two IgG-like domains of the extracellular portion of the CD80 antigen. Our data give strong support to the hypothesis that, in the presence of the first signal simulated by anti-CD3 mAb in vitro, a soluble B7-IgG fusion protein including only the extracellular portion of the CD80 molecule could, as in transfection with fulllength CD80 cDNA, boost the expression of CD80 on tumor cells and co-stimulate naïve T cells to proliferate, secrete IL-2 and thereby enhance their killing activity against tumor cells. Early in 1999, an investigation was reported (Moro et al., 1999 ) that a biotinylated B7-IgG fusion protein could induce potent anti-cancer immunity. But this approach was based on a sequential incubation of cultured tumor cells with biotinylated antibodies specific for a membrane tumor-associated antigen (TAA), avidin and biotinylated soluble B7-IgG fusion protein, which is a multistep procedure not suitable for clinical application. The rationale underlying our approach is the binding with high affinity of the Fc fragment of the fusion protein to Fc gamma receptors highly expressed on some tumor cells like AML. This binding occurs in physiological conditions. As a new type of cluster of differentiation (CD)/immunoglobulin G (IgG) fusion protein, B7-IgG has many advantages over B7 gene transfection or transduction in terms of tumor immunotherapy.
Firstly, it is soluble and can be produced in bulk in vitro by genetic engineering. Secondly, introduction of the CH domain of the heavy chain into the fusion protein gives it a longer half-life in vivo and makes it more suitable for in vivo use. Thirdly, there are investigations showing that Fc gamma receptors are highly expressed on nearly all AML cells (Notter et al., 1993) , but have a very restricted pattern of expression in normal cells (Olweus et al., 1995) . Our results prove high-level expression of CD32, the mouse IgG2b/1 Fc receptor on WEHI-3 cells. It has been established (Notter et al., 1993) that AML cells whose Fc gamma receptors were bound by an anti-CD3 mAb, like B7-IgG, were preferentially lysed in vitro by cytotoxic T lymphocytes, and most of the normal cells were spared. Taken together, these results suggest that the fusion protein has greater effects on tumor cells than on normal cells. Fourthly, by means of its IgG Fc portion, the membranebound fusion protein can enrich co-stimulatory molecules in the local microenvironment around tumor cells and magnify co-stimulatory signals, which can greatly improve anti-tumor immunity. Lastly, unlike B7 gene transfection, soluble B7-IgG can bind with high affinity to CTLA-4 on activated T cells to block negative signals triggered by it, thereby further enhancing the anti-tumor activity.
The potency of the B7-IgG fusion protein in stimulating anti-tumor immune responses suggests that it may be useful in optimizing anticancer vaccines and has clinical potential as therapy for oncology and for other clinical indications. As described previously (Oh et al., 2003) , increasing levels of costimulation, using a triad of costimulatory molecules-CD80, ICAM-1 and LFA-3-in conjunction with a vaccine, can selectively induce CTLs skewed toward higher avidity and more effective at killing tumor cells. Soluble B7-IgG fusion protein can also be used as an effective molecular adjuvant in tumor immune therapy. Intramuscular gene transfer of B7-IgG fusion gene induce potent anti-tumor immunity as an adjuvant for DNA vaccination (Zhou et al., 2003) . Leukemia may be cured by intravenous administration of the fusion protein. Indeed, the combination of conventional chemotherapy and systemic immunotherapy with soluble B7-IgG fusion protein could synergize to induce curative T-cell-dependent antitumor responses and immunologic memory in murine leukemia and lymphoma models (Runyon et al., 2001) . More recently, this fusion protein was shown to be able to induce complete regression of some solid tumors after intravenous injection if combined with regulatory T cell depletion (Liu et al., 2005) . But the efficacy lasts for only a short time because of the protein's short half-life. In addition, the safety of intravenous injection of a high dose of this fusion protein remains undetermined in spite of a research in which maximum 500 μg protein was injected to mice and did not show any in vivo toxicity (Runyon et al., 2001) . We constructed this recombinant expressing vector with a view to eradicating tumor cells by intratumor injection of this vector or infusion of fusion gene-modified T cells from donors into leukemia recipients. If so, systemic exposure to these co-stimulatory molecules and consequent in vivo toxicity will be minimized and the efficacy will last for much longer because of the persistence of gene expression.
In summary, targeting of tumor cells with the B7-IgG fusion protein is a new strategy of immunotherapy for tumors including leukemias and some solid tumors, with the potential for further preclini-cal trials and future clinical application. However, this is a manmade molecule, and it remains undetermined how this soluble molecule induces potent anti-tumor immunity; further studies are needed. From our data, it is uncertain whether this fusion molecule can interplay with its ligands in vivo and promote a tumor-specific immune response. Also, further investigation is needed to determine whether the fusion protein can do harm to the human body.
